![Chengwen Li](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Chengwen Li is the founder of GeneVentiv Therapeutics, Inc. He currently holds a position as Director at Nabgen, Inc.
Chengwen Li active positions
Companies | Position | Start |
---|---|---|
GeneVentiv Therapeutics, Inc.
![]() GeneVentiv Therapeutics, Inc. BiotechnologyHealth Technology GeneVentiv Therapeutics, Inc. is a company that is developing the first gene therapy for patients with hemophilia A or B, with or without inhibitors. The company is based in Raleigh, NC. The company's product, Genv-Hem, produces clotting factor Va, which allows for normal clotting in response to injury. Currently, there are no curative gene therapies available for patients with inhibitors. GeneVentiv Therapeutics was founded by Chengwen Li and the CEO is Damon R Race. | Founder | - |
Nabgen, Inc. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
GeneVentiv Therapeutics, Inc.
![]() GeneVentiv Therapeutics, Inc. BiotechnologyHealth Technology GeneVentiv Therapeutics, Inc. is a company that is developing the first gene therapy for patients with hemophilia A or B, with or without inhibitors. The company is based in Raleigh, NC. The company's product, Genv-Hem, produces clotting factor Va, which allows for normal clotting in response to injury. Currently, there are no curative gene therapies available for patients with inhibitors. GeneVentiv Therapeutics was founded by Chengwen Li and the CEO is Damon R Race. | Health Technology |
Nabgen, Inc. |
- Stock Market
- Insiders
- Chengwen Li